Navigation Links
Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.

EMERYVILLE, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc (NTI (TM)) (Nasdaq: NTII) announced today that Warren Wasiewski, M.D. was appointed Chief Medical Officer, effective as of November 26, 2007.

Dr. Wasiewski joined NTI in February 2007 as Vice President, Clinical Programs with primary responsibility for running the clinical trial program for Viprinex(TM), NTI's drug candidate for acute ischemic stroke that is currently in two Phase 3 clinical trials. Dr. Wasiewski is a Board Certified Pediatric Neurologist with an extensive clinical career. Prior to joining NTI, he worked at AstraZeneca where he was Sr. Medical Director of clinical research CNS/Emerging Products. At AstraZeneca, Dr. Wasiewski had responsibility for running the global SAINT trials for AstraZeneca's neuroprotectant drug candidate.

Dr. Wasiewski holds a Bachelor of Arts degree in Biology Cum Laude from Rutgers College, a Masters of Science degree in Biochemistry from State University of New York Downstate Medical Center, and a Doctorate of Medicine from State University of New York, at Buffalo.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors
2. Governor Rendell Launches Tour to Insure in Warren County; Urges Passage of Plan to Give Access to Affordable Health Insurance
3. Friends of Warren Zevon To Play at Maverick Saloon - Raising Awareness of Asbestos Cancer, Mesothelioma
4. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
5. William Moore Appointed to IRIDEX Board of Directors
6. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
7. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
8. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
9. James B. Hawkins Appointed to IRIDEX Board of Directors
10. Bryan R. Rogers Appointed President of Far West Division
11. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: